Results 161 to 170 of about 11,499 (250)

Development and Validation of High-Performance Thin Layer Chromatographic Method for the Simultaneous Estimation of Dapagliflozin and Vildagliptin in Fixed-Dose Combination. [PDF]

Turk J Pharm Sci
Krishnamoorthy YV, Azhlwar S, Krishnamoorthy V.   +2 more
europepmc   +1 more source

Effects of empagliflosin and vildagliptin on structural and functionak parametres in patients with type 2 diabetes

, 2020
A. A. Vasilieva, А. Yu. Babenko, Д. А. Лебедев, Yu. A. Kolchanova, E. R. Glavatskikh, M. Boyarinova, А. С. Алиева, E. V. Karelkina, О. М. Моисеева, А. О. Конради   +9 more
openalex   +1 more source

<i>In Vivo</i> and <i>In Silico</i> Analysis of Quercetin's Effects on Glycemic Regulation. [PDF]

Scientifica (Cairo)
Jumriani J, Aswad M, Ratnawati R, Filmaharani F, Nurhidayah A, Azmin MR, Roosevelt A, Alfiana R, Hardiyanti W, Latada NP, Mudjahid M, Nainu F.   +11 more
europepmc   +1 more source

Discovery of DiPeptidyl Peptidase-4 Gene Variants and the Associations with Efficacy of Vildagliptin in Patients with Typ e 2 Diabetes - A Pilot Study

, 2013
Obin Kwon
openalex   +1 more source

Therapeutic impact of vildagliptin vs. gliclazide on insulin resistance and advanced glycated end product levels in newly diagnosed Egyptian diabetics: a randomized controlled trial. [PDF]

Eur J Clin Pharmacol
Elemary T, Abdelrahim MEA, Nicola M, Zaafar D.   +3 more
europepmc   +1 more source

Cost-Effectiveness Analysis of d-Nav for People with Diabetes at High Risk of Neuropathic Foot Ulcers [PDF]

, 2016
Matthew Taylor, William Green
core   +1 more source

Vildagliptin modulates the microbiota and induces an immunometabolic profile compatible with neuroprotection in type 2 diabetes. [PDF]

Sci Rep
de Macedo JCC, Guadagnini D, Assalin HB, Oliveira ES, Magro DO, Alborghetti MR, Sforça ML, Rocco SA, Santos A, Saad MJA.   +9 more
europepmc   +1 more source

Vildagliptin modulates the microbiota and induces an immunometabolic neuroprotective profile

Macêdo, Juliane Colombo Carrer de, 1971-
openalex   +1 more source

Vildagliptins effekt på kardiovaskulära riskfaktorer hos typ 2-diabetespatienter

, 2019
Ljubica Ignjic
openalex   +1 more source

Comment on "SMPDL3B as a novel biomarker and therapeutic target in myalgic encephalomyelitis" critical considerations on biomarker validation and Supraphysiological drug concentrations. [PDF]

J Transl Med
Chen J, Yan L.
europepmc   +1 more source